Verastem raises $75M private placement for ovarian cancer drug launch and R&D

Verastem, Inc.

Gross proceeds of ~$75M from sale of 3.43M shares at $7.00 and 7.29M pre-funded warrants at $6.9999.
Placement led by RTW Investments; includes BVF, Nantahala, Octagon, OrbiMed, Stonepine.
Net proceeds to fund potential launch of avutometinib/defactinib in LGSOC, R&D for VS-7375, and working capital.
Pre-funded warrants exercisable at $0.0001/share, no expiration; closing expected April 28, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.